The miR-141/200c-STAT4 Axis Contributes to Leukemogenesis by Enhancing Cell Proliferation in T-PLL.
STAT4
T-PLL
T-cell lymphoma
cell proliferation
leukemogenesis
miR-141
miR-200c
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
28 Apr 2023
28 Apr 2023
Historique:
received:
27
03
2023
revised:
17
04
2023
accepted:
25
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
T-prolymphocytic leukemia (T-PLL) is a rare and mature T-cell malignancy with characteristic chemotherapy-refractory behavior and a poor prognosis. Molecular concepts of disease development have been restricted to protein-coding genes. Recent global microRNA (miR) expression profiles revealed miR-141-3p and miR-200c-3p (miR-141/200c) as two of the highest differentially expressed miRs in T-PLL cells versus healthy donor-derived T cells. Furthermore, miR-141/200c expression separates T-PLL cases into two subgroups with high and low expression, respectively. Evaluating the potential pro-oncogenic function of miR-141/200c deregulation, we discovered accelerated proliferation and reduced stress-induced cell death induction upon stable miR-141/200c overexpression in mature T-cell leukemia/lymphoma lines. We further characterized a miR-141/200c-specific transcriptome involving the altered expression of genes associated with enhanced cell cycle transition, impaired DNA damage responses, and augmented survival signaling pathways. Among those genes, we identified
Identifiants
pubmed: 37173993
pii: cancers15092527
doi: 10.3390/cancers15092527
pmc: PMC10177500
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Union
ID : ERANET-PLL (01KT1906A)
Organisme : European Union
ID : JAKSTAT-TARGET (ERAPERMED2018-066)
Organisme : Deutsche José Carreras Leukämie-Stiftung
ID : DJCLS 03 F/2016
Organisme : Köln Fortune Stiftung
ID : individual scholarships
Organisme : Academy of Finland
ID : 326238
Organisme : Academy of Finland
ID : 345803
Références
Cancers (Basel). 2019 Nov 21;11(12):
pubmed: 31766351
Nucleic Acids Res. 2014;42(17):e133
pubmed: 25063298
RNA. 2007 Jan;13(1):22-9
pubmed: 17123955
Blood. 2008 Jan 1;111(1):328-37
pubmed: 17890451
Nat Rev Immunol. 2011 Apr;11(4):239-50
pubmed: 21436836
J Oncol. 2021 Oct 12;2021:5425491
pubmed: 34675977
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
Oncogene. 2000 May 15;19(21):2577-84
pubmed: 10851056
Nat Commun. 2018 Feb 15;9(1):697
pubmed: 29449575
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
pubmed: 16166262
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Cancers (Basel). 2022 Apr 18;14(8):
pubmed: 35454943
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638338
Cancer Res. 2004 Oct 15;64(20):7579-87
pubmed: 15492285
Mol Cell. 2004 Jul 23;15(2):185-97
pubmed: 15260970
Sci Rep. 2017 Oct 19;7(1):13598
pubmed: 29051585
Mol Aspects Med. 2019 Dec;70:57-71
pubmed: 31558294
Cancers (Basel). 2021 Nov 23;13(23):
pubmed: 34884985
Cancer Res. 2022 May 3;82(9):1818-1831
pubmed: 35259248
Haematologica. 2022 Jan 01;107(1):187-200
pubmed: 33543866
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Genes (Basel). 2021 Feb 12;12(2):
pubmed: 33673143
J Invest Dermatol. 2018 Sep;138(9):2024-2032
pubmed: 29559342
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Clin Cancer Res. 2014 Jun 1;20(11):2851-61
pubmed: 24727323
Lab Invest. 2008 Aug;88(8):856-64
pubmed: 18521064
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
J Cell Physiol. 2018 Aug;233(8):5574-5588
pubmed: 29521426
World J Gastroenterol. 2015 Apr 7;21(13):3983-93
pubmed: 25852285
Oncotarget. 2016 Nov 8;7(45):73558-73572
pubmed: 27713153
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Blood. 2004 Jul 15;104(2):328-35
pubmed: 15044256
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Perspect Clin Res. 2016 Apr-Jun;7(2):68-74
pubmed: 27141472
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Blood. 2019 Oct 3;134(14):1132-1143
pubmed: 31292114
J Exp Clin Cancer Res. 2018 Jan 31;37(1):18
pubmed: 29386059
Science. 2010 Jan 8;327(5962):198-201
pubmed: 19965718
J Immunol. 2002 Oct 15;169(8):4388-98
pubmed: 12370372
Oncotarget. 2016 Aug 30;7(35):57086-57098
pubmed: 27494881
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Oncol Lett. 2021 Feb;21(2):137
pubmed: 33552256
Ann Oncol. 2017 Jul 01;28(7):1554-1559
pubmed: 28379307
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124
pubmed: 32034661
Oncotarget. 2015 Mar 30;6(9):6472-98
pubmed: 25762624
Onco Targets Ther. 2021 Jan 05;13:13479-13490
pubmed: 33447052
Cell Cycle. 2014;13(18):2975-82
pubmed: 25486484
Int J Cancer. 2009 Apr 15;124(8):1756-66
pubmed: 19115200
Oncol Lett. 2019 Oct;18(4):3994-4007
pubmed: 31565080
Haematologica. 2022 Jan 01;107(1):143-153
pubmed: 33596640